1. Home
  2. IQ vs ARDX Comparison

IQ vs ARDX Comparison

Compare IQ & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo iQIYI Inc.

IQ

iQIYI Inc.

HOLD

Current Price

$1.42

Market Cap

1.3B

ML Signal

HOLD

Logo Ardelyx Inc.

ARDX

Ardelyx Inc.

HOLD

Current Price

$6.33

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IQ
ARDX
Founded
2009
2007
Country
China
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Video Chains
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.3B
IPO Year
2017
2014

Fundamental Metrics

Financial Performance
Metric
IQ
ARDX
Price
$1.42
$6.33
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
7
Target Price
$2.91
$15.14
AVG Volume (30 Days)
8.2M
3.0M
Earning Date
05-20-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,607,000.00
Revenue This Year
$0.45
$37.75
Revenue Next Year
$3.76
$34.24
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.18
$3.50
52 Week High
$2.76
$8.40

Technical Indicators

Market Signals
Indicator
IQ
ARDX
Relative Strength Index (RSI) 54.56 59.74
Support Level $1.19 $5.49
Resistance Level $2.16 $6.70
Average True Range (ATR) 0.07 0.24
MACD 0.03 0.11
Stochastic Oscillator 92.00 87.88

Price Performance

Historical Comparison
IQ
ARDX

About IQ iQIYI Inc.

Iqiyi is a streaming video-on-demand company in China that generates revenue mostly on a subscription basis. The platform also provides user-generated content to nonpaying users, monetized through ads. The company self-produces much of the subscription content and also generates revenue through content distribution, gaming, and IP licensing. Iqiyi competes directly with Tencent Video, Alibaba's Youku, ByteDance's MangoTV, and Bilibili. The company is 45% and 5% owned by Baidu and Xiaomi, respectively.

About ARDX Ardelyx Inc.

Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

Share on Social Networks: